We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) (BEGIN)

This study has been terminated.
(The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00539838
First Posted: October 5, 2007
Last Update Posted: May 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Genentech, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: January 17, 2013